Jazz Pharmaceuticals PLC (JAZZ)

Name: Jazz Pharmaceuticals PLC (JAZZ) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Jazz Pharmaceuticals PLC (JAZZ)

Stock Card

$250.68

$6.14 (2.51%)

As on 31-Aug-2026 16:27EDT

Market cap

$15,874 Mln

Revenue (TTM)

$4,601 Mln

P/E Ratio

16.7

P/B Ratio

3.4

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

Jazz Pharmaceuticals PLC (JAZZ) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 241.39 High: 252.72

52 Week Range

Low: 123.89 High: 266.38

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

0.2 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

11.4
Debt to Equity

0.7
Book Value

$--
EPS

$14.6
Face value

--
Shares outstanding

64,914,577

10 Years Aggregate

CFO

$7,838.78 Mln

EBITDA

$8,672.27 Mln

Net Profit

$2,353.42 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Jazz Pharmaceuticals PLC (JAZZ)	47.5	-3.0	6.0	96.2	19.9	13.8	7.1
BSE Sensex^*	-9.3	-1.7	2.7	-3.8	5.8	5.9	10.4
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 31-Aug-2026 | *As on 01-Sep-2026 | #As on 26-Oct-2023

Company	2025	2023	2022	2021	2020	2019
Jazz Pharmaceuticals PLC (JAZZ)	38.0	-22.8	25.0	-22.8	10.6	20.4
S&P Small-Cap 600	4.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Jazz Pharmaceuticals PLC (JAZZ)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and... idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland. Read more

Co-Founder, Chairman & CEO

Mr. Bruce C. Cozadd
Co-Founder, Chairman & CEO

Mr. Bruce C. Cozadd
Headquarters

Dublin
Website

https://www.jazzpharma.com

FAQs for Jazz Pharmaceuticals PLC (JAZZ)

What is the current share price of Jazz Pharmaceuticals PLC (JAZZ) Today?

The share price of Jazz Pharmaceuticals PLC (JAZZ) is $250.68 (NASDAQ) as of 31-Aug-2026 16:27 EDT. Jazz Pharmaceuticals PLC (JAZZ) has given a return of 19.93% in the last 3 years.

What is the current PB & PE ratio of Jazz Pharmaceuticals PLC (JAZZ)?

The P/E ratio of Jazz Pharmaceuticals PLC (JAZZ) is 16.74 times as on 28-Aug-2026.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-29.11	2.40
2024	13.52	1.85
2023	20.66	2.29
2022	-44.83	3.26
2021	-23.82	1.98

What is the 52 Week High and Low of Jazz Pharmaceuticals PLC (JAZZ)?

The 52-week high and low of Jazz Pharmaceuticals PLC (JAZZ) are Rs 266.38 and Rs 123.89 as of 01-Sep-2026.

What is the market cap of Jazz Pharmaceuticals PLC (JAZZ)?

Jazz Pharmaceuticals PLC (JAZZ) has a market capitalisation of $ 15,874 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Jazz Pharmaceuticals PLC (JAZZ)?

Before investing in Jazz Pharmaceuticals PLC (JAZZ), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.